Format

Send to

Choose Destination
Eur Neuropsychopharmacol. 2010 Jun;20(6):357-68. doi: 10.1016/j.euroneuro.2010.02.008. Epub 2010 Mar 11.

The involvement of GSK3beta in bipolar disorder: integrating evidence from multiple types of genetic studies.

Author information

1
Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, B01.206, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. j.luykx@umcutrecht.nl

Abstract

We aimed to get a comprehensive insight into the genetic evidence supporting the role of GSK3beta in bipolar disorder (BD). Using broad searches in NCBI's PubMed and the Genetic Association Database we looked for association, whole-genome linkage, genome-wide association, gene expression, pharmocogenomic, epigenetic, cytogenetic, and mouse model studies performed for BD until July 2009. Per gene, we rated the degree of converging evidence across these types of genetic studies. The genes most consistently associated with BD in the genetic studies we reviewed were GSK3beta , GRK3, 5-HTTLPR, GRIN3, COMT, and GLUR3. GSK3beta stood out as it was implicated in at least five types of genetic studies. Although our results are limited by design differences of included studies and possibly by publication bias, GSK3beta is a plausible candidate gene for BD from a pharmacological and a genetic perspective. Future studies investigating the effects of GSK3beta manipulation in BD seem warranted.

PMID:
20226637
DOI:
10.1016/j.euroneuro.2010.02.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center